DOCSLIB.ORG

2012 Aug (120): Treatment Guidelines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2012 Aug (120): Treatment Guidelines Treatment Guidelines from The Medical Letter® Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication IN THIS ISSUE (starts on next page) Antifungal Drugs...................................................................p 61 Important Copyright Message The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited. Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited. By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc. For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769 FORWARDING OR COPYING IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call: 800-211-2769 Treatment Guidelines from The Medical Letter® Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication Volume 10 (Issue 120) August 2012 www.medicalletter.org Tables 1. Treatment of Fungal Infections Pages 62-63 Take CME exams 2. Amphotericin B Formulations Page 66 3. Treatment of Onychomycosis and Tinea Page 67 Pedis Antifungal Drugs The drugs of choice for treatment of fungal infections ties, including brachycephaly, cleft palate and congen- are listed in the table that begins on page 62. Some of ital heart disease, have been reported in infants the indications and dosages recommended here have exposed in utero to high doses (400-800 mg/day) of not been approved by the FDA. More detailed guide- fluconazole during most or all of the first trimester.2 lines for some of these infections are available online from the Infectious Diseases Society of America Drug Interactions – Fluconazole is a strong inhibitor (www.idsociety.org). of CYP2C9 and 2C19 and a moderate inhibitor of CYP3A4; it can increase serum concentrations of AZOLES drugs metabolized by these pathways. Concurrent use of fluconazole with other drugs known to prolong the Azole antifungal agents inhibit synthesis of ergosterol, an QT interval, particularly those metabolized by essential component of the fungal cell membrane. They CYP2C9, 2C19 or 3A4, may increase the risk of QT vary in their spectrum of activity, oral bioavailability, prolongation and torsades de pointes.3 Taking flucona- adverse effects and potential for drug-drug interactions. zole with the potent CYP enzyme inducer rifampin can reduce fluconazole serum concentrations, possibly FLUCONAZOLE — Fluconazole (Diflucan, and to subtherapeutic levels. others) is active against most Candida species other than C. krusei, which is intrinsically resistant, and ITRACONAZOLE — Itraconazole (Sporanox, and many strains of C. glabrata, which are variably others) has a broader spectrum of activity than resistant. It has good activity against Coccidioides fluconazole. It is active against a wide variety of fungi spp. and Cryptococcus neoformans and some activity 1 including C. neoformans, Aspergillus spp., Blastomyces against Histoplasma capsulatum. The drug has no dermatitidis, Coccidioides spp., H. capsulatum, clinically significant activity against most molds, Paracoccidioides brasiliensis, Sporothrix spp., and der- including Aspergillus spp., Fusarium spp., and the matophytes. It is also active against most species of Mucorales (formerly called Zygomycetes), such as Candida. Itraconazole has no clinically significant Mucor spp. and Rhizopus spp.. activity against Fusarium spp. or the Mucorales and has variable activity against Scedosporium spp.. Adverse Effects – Fluconazole is generally well tol- erated. Headache, gastrointestinal distress, facial Itraconazole is available in capsules and as an oral edema, rash and pruritus can occur. Stevens-Johnson solution; an IV formulation is no longer available in syndrome, anaphylaxis, hepatic toxicity, leukopenia the US. The oral solution is more bioavailable than the and hypokalemia have been reported. QT prolongation capsules. The capsules should be taken with food, and torsades de pointes have also been reported. while the solution is absorbed best without food. Pregnancy – Fluconazole is teratogenic in animals. It Adverse Effects – The most common adverse effects of is classified as pregnancy category C (risk cannot be oral itraconazole are nausea, diarrhea, vomiting and ruled out) when used in a low dose (single dose of 150 rash. Stevens-Johnson syndrome and serious hepatic mg) for vaginal candidiasis. It is classified as preg- toxicity can occur. Negative inotropic effects, peripher- nancy category D (positive evidence of risk) when al and pulmonary edema, and congestive heart failure used for any other indication. Congenital abnormali- have been reported; itraconazole should not be used in Federal copyright law prohibits unauthorized reproduction by any means and imposes severe fines. 61 Antifungal Drugs Table 1. Treatment of Fungal Infections Infection Drug of Choice1 Some Alternatives1 Aspergillosis Voriconazole 6 mg/kg IV q12h x 2 doses, A lipid formulation of amphotericin B2 IV then 4 mg/kg IV q12h3 or 200 mg4 PO bid Posaconazole 200 mg PO qid, then 400 mg bid until resolved Caspofungin 70 mg IV x 1, then 50 mg IV 1x/d Micafungin 100-150 mg IV 1x/d Blastomycosis5 Mild to moderate Itraconazole 200 mg PO tid x 3 d, then bid Fluconazole 400-800 mg PO 1x/d6-8 x 6-12 mo Moderately severe Amphotericin B2 0.7-1 mg/kg/d IV x 1-2 wks, to severe then itraconazole 200 mg PO tid x 3 d, then 200 mg bid x 6-12 mos9 Candidiasis Vulvovaginal10 Intravaginal butoconazole, clotrimazole, miconazole, nystatin, tioconazole, terconazole 1x/d x 1-14 d11 or Fluconazole 150 mg PO once12 Itraconazole 200 mg PO bid x 1d Recurrent Topical or oral azole x 10-14 d, Clotrimazole 200 mg 2x/wk topically then fluconazole 150 mg PO 1x/wk x 6 mos or 500 mg 1x/wk intravaginally Urinary13 Fluconazole 200 mg (3 mg/kg)8,14 IV or PO Amphotericin B2 0.3-0.6 mg/kg/d14 IV x 1-7 d 1x/d x 2 wks Oropharyngeal15-19 Fluconazole 100-200 mg (3 mg/kg)8 PO Itraconazole20 200 mg PO 1x/d x 7-14 d Posaconazole 400 mg PO bid x 3 d, then 400 mg 1x/d Voriconazole 200 mg3,4 PO bid Amphotericin B oral susp 100 mg/mL qid An echinocandin: Micafungin 150 mg IV 1x/d Caspofungin 50 mg IV 1x/d Anidulafungin 200 mg IV 1x/d Amphotericin B 0.3 mg/kg/d IV Esophageal17,18,21 Fluconazole 200-400 mg (3-6 mg/kg)8 PO Itraconazole20 200 mg PO 1x/d or 400 mg IV 1x/d Posaconazole 400 mg PO bid Voriconazole 200 mg3,4 PO or IV bid Amphotericin B2 0.3-0.7 mg/kg/d IV An echinocandin: Micafungin 150 mg IV 1x/d Caspofungin 50 mg IV 1x/d Anidulafungin 200 mg IV 1x/d Candidemia and Fluconazole23 400 mg (6 mg/kg)6,8 IV 1x/d Amphotericin B2 0.5-1 mg/kg/d IV Invasive Candidiasis17,22 or An echinocandin24 Caspofungin 70 mg x 1, then 50 mg IV 1x/d Micafungin 100 mg IV 1x/d Anidulafungin 200 mg x 1, then 100 mg IV 1x/d 1. Usual adult dosage. Some drugs may need dosage adjustment for renal or hepatic dysfunction or when used with interacting drugs. The optimal duration of treatment with antifungal drugs is often unclear. Depending on the disease and its severity, they may be continued for weeks or months or, particularly in immunocompromised patients, indefinitely. Some of these indications and dosages have not been approved by the FDA. 2. Lipid-based formulations are often preferred, especially in patients at risk for nephrotoxicity or who are expected to receive a long course of therapy. Usual doses of lipid-based formulations for treatment of invasive fungal infection are: amphotericin B lipid complex (Abelcet) 5 mg/kg/d; liposomal amphotericin B (AmBisome) 3-5 mg/kg/d; amphotericin B cholesteryl sulfate (Amphotec) 3-4 mg/kg/d. For treatment of mucormycosis or fusariosis, the lipid formulation dosage is >5 mg/kg/d. For treatment of cryptococcal meningitis in HIV patients, the dosage of AmBisome is 4-6 mg/kg/d. The usual dosage of amphotericin B deoxycholate for treatment of systemic fungal infections is 0.7-1 mg/kg/d. 3. Children may need higher doses. According to the manufacturer, serum concentrations in children with doses of 4 mg/kg are similar to those in adults given 3 mg/kg. In the European Union, where voriconazole is licensed for use in children 2-11 years old, the recommended maintenance dosage is 8 mg/kg IV bid or 200 mg PO bid (LE Friberg et al, Antimicrob Agents Chemother 2012; 56:3032). 4. Some Medical Letter reviewers recommend a weight-based dose of oral voriconazole (4 mg/kg PO bid) rather than the FDA-approved dose of 200 mg PO bid because of the potential for subtherapeutic serum concentrations. According to the manufacturer, adults who weigh <40 kg should receive half the oral maintenance dose. 5. Patients with severe illness or CNS involvement should receive a lipid formulation of amphotericin B for 4-6 weeks, followed by an azole for at least 1 year. 6. In general, a loading dose of twice the daily dose is recommended on the first day of therapy. 7. For use in patients who cannot tolerate itraconazole or amphotericin B. 8. Children need higher doses of fluconazole than adults do. According to the manufacturer, an adult dose of 100 mg is equivalent to a pediatric dose of 3 mg/kg. 9. For disseminated extrapulmonary or osteoarticular disease, treat for at least 12 months.
Load more

Recommended publications
  • Copper(II) and Zinc(II) Complexes with the Clinically Used Fluconazole: Comparison of Antifungal Activity and Therapeutic Potential
    pharmaceuticals Article Copper(II) and Zinc(II) Complexes with the Clinically Used Fluconazole: Comparison of Antifungal Activity and Therapeutic Potential Nevena Lj. Stevanovi´c 1 , Ivana Aleksic 2, Jakob Kljun 3 , Sanja Skaro Bogojevic 2 , Aleksandar Veselinovic 4, Jasmina Nikodinovic-Runic 2,* , Iztok Turel 3,* , Miloš I. Djuran 5,* and Biljana Ð. Gliši´c 1,* 1 Department of Chemistry, Faculty of Science, University of Kragujevac, R. Domanovi´ca12, 34000 Kragujevac, Serbia; [email protected] 2 Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11042 Belgrade, Serbia; [email protected] (I.A.); [email protected] (S.S.B.) 3 Faculty of Chemistry and Chemical Technology, University of Ljubljana, Veˇcnapot 113, SI-1000 Ljubljana, Slovenia; [email protected] 4 Department of Chemistry, Faculty of Medicine, University of Niš, Blvd. Dr Zorana Djindjica 81, 18108 Niš, Serbia; [email protected] 5 Department of Chemical and Biological Sciences, Serbian Academy of Sciences and Arts, Knez Mihailova 35, 11000 Belgrade, Serbia * Correspondence: [email protected] (J.N.-R.); [email protected] (I.T.); [email protected] (M.I.D.); [email protected] (B.Ð.G.); Tel.: +381-11-397-6034 (J.N.-R.); +386-1-47-98-525 (I.T.); +381-34-300-251 (M.I.D.); +381-34-336-223 (B.Ð.G.) Abstract: Copper(II) and zinc(II) complexes with clinically used antifungal drug fluconazole (fcz), . · {[CuCl2(fcz)2] 5H2O}n, 1, and {[ZnCl2(fcz)2] 2C2H5OH}n, 2, were prepared and characterized by spectroscopic and crystallographic methods.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Candida Auris
    microorganisms Review Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities Suhail Ahmad * and Wadha Alfouzan Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait; [email protected] * Correspondence: [email protected]; Tel.: +965-2463-6503 Abstract: Candida auris, a recently recognized, often multidrug-resistant yeast, has become a sig- nificant fungal pathogen due to its ability to cause invasive infections and outbreaks in healthcare facilities which have been difficult to control and treat. The extraordinary abilities of C. auris to easily contaminate the environment around colonized patients and persist for long periods have recently re- sulted in major outbreaks in many countries. C. auris resists elimination by robust cleaning and other decontamination procedures, likely due to the formation of ‘dry’ biofilms. Susceptible hospitalized patients, particularly those with multiple comorbidities in intensive care settings, acquire C. auris rather easily from close contact with C. auris-infected patients, their environment, or the equipment used on colonized patients, often with fatal consequences. This review highlights the lessons learned from recent studies on the epidemiology, diagnosis, pathogenesis, susceptibility, and molecular basis of resistance to antifungal drugs and infection control measures to combat the spread of C. auris Citation: Ahmad, S.; Alfouzan, W. Candida auris: Epidemiology, infections in healthcare facilities. Particular emphasis is given to interventions aiming to prevent new Diagnosis, Pathogenesis, Antifungal infections in healthcare facilities, including the screening of susceptible patients for colonization; the Susceptibility, and Infection Control cleaning and decontamination of the environment, equipment, and colonized patients; and successful Measures to Combat the Spread of approaches to identify and treat infected patients, particularly during outbreaks.
    [Show full text]
  • Step Therapy Criteria Drug Class Topical Antifungal Agents (Brand Products Only)
    STEP THERAPY CRITERIA DRUG CLASS TOPICAL ANTIFUNGAL AGENTS (BRAND PRODUCTS ONLY) BRAND NAME (generic) ECOZA (econazole) ERTACZO (sertaconazole) EXELDERM (sulconazole nitrate) LOPROX (ciclopirox shampoo) LOTRISONE (clotrimazole/betamethasone) LUZU (luliconazole) MENTAX (butenafine) NAFTIN (naftifine) OXISTAT (oxiconazole) VUSION (miconazole/zinc oxide/white petrolatum) XOLEGEL (ketoconazole) Antifungal Topical Step Therapy Policy 06-2017 CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members. CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). ® Registered trademark of the Blue Cross and Blue Shield Association Page 1 of 4 Status: CVS Caremark Criteria Type: Initial Step Therapy; Post Step Therapy Prior Authorization POLICY FDA-APPROVED INDICATIONS Ecoza Ecoza topical 1% foam is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton
    [Show full text]
  • Mycamine (Micafungin) Safety and Drug Utilization Review
    Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review Date: February 26, 2016 Safety Evaluator: Timothy Jancel, PharmD, BCPS (AQ-ID) Division of Pharmacovigilance II (DPV II) Drug Use Analyst: LCDR Justin Mathew, PharmD Division of Epidemiology II (DEPI II) Team Leaders: Kelly Cao, PharmD Division of Pharmacovigilance II (DPV II) Rajdeep Gill, PharmD Division of Epidemiology II (DEPI II) Deputy Directors: S. Christopher Jones, PharmD, MS, MPH Division of Pharmacovigilance II (DPV II) LCDR Grace Chai, Pharm.D Division of Epidemiology II (DEPI II) Product Name(s): Mycamine® (micafungin) Pediatric Labeling Approval Date: June 21, 2013 Application Type/Number: NDA 021506 Applicant/Sponsor: Astellas OSE RCM #: 2015-1945 **This document contains proprietary drug use data obtained by FDA under contract. The drug use data/information cannot be released to the public/non-FDA personnel without contractor approval obtained through the FDA/CDER Office of Surveillance and Epidemiology.** Reference ID: 3893564 TABLE OF CONTENTS Executive Summary.........................................................................................................................3 1 Introduction..............................................................................................................................4 1.1 Pediatric Regulatory History.............................................................................................4
    [Show full text]
  • Vaginal Delivery System
    (19) & (11) EP 2 062 568 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.05.2009 Bulletin 2009/22 A61K 9/00 (2006.01) (21) Application number: 07397042.8 (22) Date of filing: 22.11.2007 (84) Designated Contracting States: • Hanes, Vladimir AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Tarrytown, NY 10591 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Keinänen, Antti SI SK TR 20540 Turku (FI) Designated Extension States: • Holmberg, Svante AL BA HR MK RS 20900 Turku (FI) • Nikander, Hannu (71) Applicant: Bayer Schering Pharma Oy 21330 Paattinen (FI) 20210 Turku (FI) (74) Representative: Matilainen, Mirja Helena et al (72) Inventors: Oy Jalo Ant-Wuorinen AB, • Talling, Christine Iso Roobertinkatu 4-6 A 20610 Turku (FI) 00120 Helsinki (FI) (54) Vaginal delivery system (57) The present invention is related to an intravag- brane (3) encasing the core, said core and membrane inal delivery system for the controlled release of a pro- essentially consisting of a same or different polymer com- gestogen and an estrogen, comprising additionally a position, wherein at cast one of the cores comprises a therapeutically active or a health-promoting substance progestogen or a mixture of a progestogen and an es- (1) capable of giving and/or enhancing the protection trogen, and another core may comprise an estrogen or against bacterial and fungal infections, and/or enhancing a progestogen, and wherein the membrane or the surface the protection against sexually transmitted diseases. The of the membrane or at least one of the cores comprises delivery system consists of one or more compartments said therapeutically active or a health-promoting sub- (2,4,5), one of each comprising a core (7) and a mem- stance.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • Vaginal Yeast Infections Yeast Are Caused Byinfection an Overgrowth of Yeast in the Vagina
    •Vaginal Yeast infections Yeast are caused byInfection an overgrowth of yeast in the vagina. • Yeast infections can be treated with over-the-counter medications. • Many yeast infections can be treated without seeing a medical provider. Symptoms: • Vaginal Itching, burning, swelling • Vaginal discharge (thick white vaginal discharge that looks like cottage cheese and does not have a bad smell) • May have pain during sex • May be worse the week before your period Self-care measures: • Use an over-the-counter medication for vaginal yeast infections. These antifungal medications should contain butoconazole, clotrimazole, miconazole, or tioconazole and should be used for 3-7 days. Follow directions on medication insert. Note: Over-the-counter medications are available at the University Health Center Pharmacy (first floor of Student Success Center), local pharmacies, grocery stores and superstores (examples - Walmart or Target). • Change tampons, pads and panty liners often • Do wear underwear with a cotton crotch • Apply a cool compress to labia for comfort • Do not douche or use vaginal sprays • Do not wear tight underwear and do not wear underwear to sleep • Avoid hot tubs Limit spread to others: • It is possible to spread yeast infections to your partner(s) during vaginal, oral or anal sex. • If your partner is a male, the risk is low. Some men get an itchy rash on their penis. • If this happens have your partner see a medical provider. • If your partner is a female, you may spread the yeast infection to her. • She should be treated if she
    [Show full text]
  • The Neosartorya Fischeri Antifungal Protein 2 (NFAP2)
    International Journal of Molecular Sciences Article The Neosartorya fischeri Antifungal Protein 2 (NFAP2): A New Potential Weapon against Multidrug-Resistant Candida auris Biofilms Renátó Kovács 1,2,3,* , Fruzsina Nagy 1,4, Zoltán Tóth 1,4,5, Lajos Forgács 1,4, Liliána Tóth 6,7, Györgyi Váradi 8, Gábor K. Tóth 8,9, Karina Vadászi 1, Andrew M. Borman 10,11 ,László Majoros 1 and László Galgóczy 6,7 1 Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary; [email protected] (F.N.); [email protected] (Z.T.); [email protected] (L.F.); [email protected] (K.V.); [email protected] (L.M.) 2 Faculty of Pharmacy, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary 3 Department of Metagenomics, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary 4 Doctoral School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary 5 Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary 6 Institute of Plant Biology, Biological Research Centre, Temesvári krt. 62, 6726 Szeged, Hungary; [email protected] (L.T.); [email protected] (L.G.) 7 Department of Biotechnology, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, 6726 Szeged, Hungary 8 Department of Medical Chemistry, Faculty of Medicine, University of Szeged, Dóm tér 8, 6720 Szeged, Hungary; [email protected] (G.V.); [email protected]
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Lactoferrin, Chitosan and Melaleuca Alternifolia—Natural Products That
    b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 9 (2 0 1 8) 212–219 ht tp://www.bjmicrobiol.com.br/ Review Lactoferrin, chitosan and Melaleuca alternifolia—natural products that show promise in candidiasis treatment ∗ Lorena de Oliveira Felipe , Willer Ferreira da Silva Júnior, Katialaine Corrêa de Araújo, Daniela Leite Fabrino Universidade Federal de São João del-Rei/Campus Alto Paraopeba, Minas Gerais, MG, Brazil a r t i c l e i n f o a b s t r a c t Article history: The evolution of microorganisms resistant to many medicines has become a major chal- Received 18 August 2016 lenge for the scientific community around the world. Motivated by the gravity of such a Accepted 26 May 2017 situation, the World Health Organization released a report in 2014 with the aim of providing Available online 11 November 2017 updated information on this critical scenario. Among the most worrying microorganisms, Associate Editor: Luis Henrique species from the genus Candida have exhibited a high rate of resistance to antifungal drugs. Guimarães Therefore, the objective of this review is to show that the use of natural products (extracts or isolated biomolecules), along with conventional antifungal therapy, can be a very promising Keywords: strategy to overcome microbial multiresistance. Some promising alternatives are essential Candida oils of Melaleuca alternifolia (mainly composed of terpinen-4-ol, a type of monoterpene), lacto- Lactoferrin ferrin (a peptide isolated from milk) and chitosan (a copolymer from chitin).
    [Show full text]
  • Topical Corticosteroids and Fungal Keratitis: a Review of the Literature and Case Series
    Journal of Clinical Medicine Review Topical Corticosteroids and Fungal Keratitis: A Review of the Literature and Case Series Karl Anders Knutsson 1,*, Alfonso Iovieno 2,3, Stanislav Matuska 1, Luigi Fontana 2 and Paolo Rama 1 1 Cornea and Ocular Surface Unit, San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] (S.M.); [email protected] (P.R.) 2 Arcispedale Santa Maria Nuova—IRCCS, 42123 Reggio Emilia, Italy; [email protected] (A.I.); [email protected] (L.F.) 3 Department of Ophthalmology, University of British Columbia, Vancouver, BC V6T 1Z, Canada * Correspondence: [email protected] or [email protected]; Tel./Fax: +39-022-6432-648 Abstract: The management of fungal keratitis is complex since signs and symptoms are subtle and ocular inflammation is minimal in the preliminary stages of infection. Initial misdiagnosis of the condition and consequent management of inflammation with corticosteroids is a frequent occurrence. Topical steroid use is considered to be a principal factor for development of fungal keratitis. In this review, we assess the studies that have reported outcomes of fungal keratitis in patients receiving steroids prior to diagnosis. We also assess the possible rebound effect present when steroids are abruptly discontinued and the clinical characteristics of three patients in this particular clinical scenario. Previous reports and the three clinical descriptions presented suggest that in fungal keratitis, discontinuing topical steroids can induce worsening of clinical signs. In these cases, we recommend to slowly taper steroids and continue or commence appropriate antifungal therapy. Citation: Knutsson, K.A.; Iovieno, A.; Keywords: fungal keratitis; topical corticosteroids; topical steroids; rebound effect Matuska, S.; Fontana, L.; Rama, P.
    [Show full text]